An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol

International Journal of Pharmaceutics

Volumn 287, Issue 1-2, 2004, Pages 79-87

  Weda, M ^a   Zanen, P ^b   Boer, A H De ^c   Barends, D M ^a   Frijlink, H W ^c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b 3435 CM N   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Correlation; Heart rate; Impactor; Inhalation powder; Potassium; Salbutamol

Indexed keywords

POTASSIUM; SALBUTAMOL;

ACCURACY; ADULT; AEROSOL; ANDERSEN CASCADE IMPACTOR; APPARATUS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG SAFETY; DRY POWDER; FEMALE; HEART RATE; HUMAN; IN VITRO SELECTION; IN VIVO STUDY; MALE; MULTISTAGE LIQUID IMPINGER; NORMAL HUMAN; PARTICLE SIZE; POTASSIUM BLOOD LEVEL; POWDER INHALER; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; POTASSIUM;

EID: 8444238913     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.08.017     Document Type: Article

References (24)

1. B. Berner, B. Fyrnys, and A.H. de Boer ASTA Medica multi dose dry powder inhaler R.N. Dalby P.R. Byron S.J. Farr Respiratory Drug Delivery VI 1998 Interpharm Press Buffalo Grove 475 477
2. H. Chrystyn, S.A. Corlett, and V. Silkstone Lung bioavailability of generic and innovator salbutamol MDIs Thorax 51 1996 658
3. European Pharmacopoeia, 2003. Preparations for inhalation: aerodynamic assessment of fine particles. In: European Pharmacopoeia Convention, Council of Europe, Strasbourg, France, pp. 209-219.
4. ® A multidose dry powder inhaler Drugs 63 2003 2437 2445
5. 2-adrenoreceptor-mediated responses to inhaled salbutamol Br. J. Clin. Pharmacol. 51 2001 359 362
6. R.J. Hancox, P. Subbarao, D. Kamada, R.M. Watson, F.E. Hargreave, and M.D. Inman Beta2-agonist tolerance and exercise-induced bronchospasm Am. J. Respir. Crit. Care Med. 165 2002 1068 1070
7. J. Heyder, J. Gebhart, G. Rudolf, C.F. Schiller, and W. Stahlhofen Deposition of particles in the human respiratory tract in the size range 0.005-15 μm J. Aerosol. Sci. 17 1986 811 825
8. R. Janssen, M. Weda, M.B. Ekkelenkamp, J.-W.J. Lammers, and P. Zanen Metal versus plastic spacers: an in vitro and in vivo comparison Int. J. Pharm. 245 2002 93 98
9. E.C. Kleerup, D.P. Tashkin, A.C. Cline, and B.P. Ekholm Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma Chest 109 1996 702 707
10. B.L. Laube, R. Jashnani, and R.N. Dalby Predicting in vivo lung deposition of cromolyn sodium from in vitro estimates J. Aerosol. Med. 11 1998 S35 S42
11. C.L. Leach Improved delivery of inhaled steroids to the large and small airways. Respir. Med. 92 1998 3 8
12. M.D. Louey, S. Razia, and P.J. Stewart Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures Int. J. Pharm. 252 2003 87 98
13. S.C. Nichols Andersen Cascade Impactor; calibration and mensuration issues for the standard and modified impactor Pharmeuropa 12 2000 598 602
14. R. Pauwels, S.P. Newman, and L. Borgstrom Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers Eur. Respir. J. 10 1997 2127 2138
15. J.P. Seale, and L.I. Harrison Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir. Med. 92 1998 9 15
16. O.R. Seppala, E. Aalto, T. Annila, T. Hakonen, E. Lukkari-Lax, T. Jouhikainen, M.M. Nieminen, and K. Liipp The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices Respir. Med. 95 2001 949 953
17. V.L. Silkstone, J.H. Dennis, C.A. Pieron, and H. Chrystyn An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems J. Aerosol. Med. 15 2002 251 259
18. O.S. Usmani, M.F. Biddiscombe, J.A. Nightingale, S.R. Underwood, and P.J. Barnes The effect of brochodilator particle size in asthmatics using monodisperse aerosols J. Appl. Physiol. 95 2003 2106 2112
19. H.J. van der Woude, T.H. Winter, and R. Aalbers Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists Thorax 56 2001 529 535
20. M. Weda, E.R.M. Geuns, R.C.R. Vermeer, N.R.A. Buiten, K. Hendriks-de Jong, A. Bult, P. Zanen, and D.M. Barends Equivalence testing and equivalence limits of metered-dose inhalers and dry powder inhalers measured by in vitro impaction Eur. J. Pharm. Biopharm. 49 2000 295 302
21. M. Weda, P. Zanen, A.H. de Boer, D. Gjaltema, A. Ajaoud, D.M. Barends, and H.W. Frijlink Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy Int. J. Pharm. 249 2002 247 255
22. P. Zanen, T.L. Go, and J.-W.J. Lammers The optimal particle size for β-adrenergic aerosols in mild asthmatics Int. J. Pharm. 107 1994 211 217
23. P. Zanen, and J.-W.J. Lammers Reducing adverse effects of inhaled fenoterol through optimization of the aerosol formulation J. Aerosol. Med. 12 1999 241 247
24. X.M. Zeng, G.P. Martin, C. Marriott, and J. Pritchard The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates J. Pharm. Pharmacol. 52 2000 1211 1221